← Back to headlines
Vertex Pharmaceuticals climbs on positive interim data from IgAN phase 3 trial
Vertex Pharmaceuticals stock is rising following the release of positive interim data from its Phase 3 clinical trial for IgAN.
10 Mar, 08:50 — 10 Mar, 08:50
Sources
Showing 1 of 1 sources
